Jiangsu Hengrui Pharmaceuticals Faces FDA Setback with Warning Letter for Quality Control Issues
Jiangsu Hengrui Pharmaceuticals (SHA: 600276), a prominent player in China’s pharmaceutical industry, has received a...
Ocumension Therapeutics and Shandong Boan Biotechnology File for Market Approval of Biosimilar Aflibercept in China
Ocumension Therapeutics (HKG: 1477) and Shandong Boan Biotechnology Co., Ltd (HKG: 6955) have jointly announced...
Sino Biopharmaceutical’s Anlotinib Achieves Milestones in Phase III Trial for Soft-Tissue Sarcoma
Sino Biopharmaceutical Ltd (HKG: 1177), a leading pharmaceutical company based in China, has announced positive...
Full-Life Technologies Strikes USD 571.5 Million Licensing Deal with SK Biopharmaceuticals for Radiopharmaceutical Asset
Full-Life Technologies Ltd, a globally integrated radiotherapeutics company with a presence in Belgium, Germany, and...
I-Mab Shakes Up Leadership with New Chairman and Interim CEO Appointments
I-Mab (NASDAQ: IMAB), a clinical-stage biopharmaceutical company, has announced significant changes to its leadership structure....
United Imaging Expands Latin America Footprint with Pediatric uMI 550 PET/CT Launch in Mexico
United Imaging, a leading Chinese medical device manufacturer, has announced the launch of its uMI...
MGI Tech Partners with Predica Diagnostics to Advance RNA Sequencing in Cancer Detection
MGI Tech Co., Ltd, a leading gene sequencing specialist based in China, has announced a...
Eli Lilly’s Lupus Treatment LY3361237 Misses Mark in Phase II Trial
Eli Lilly & Co. (NYSE: LLY) has encountered a setback in its drug development pipeline...
BeiGene Receives NMPA Greenlight for BG-C9074 Clinical Trial in Advanced Solid Tumors
BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced that the National Medical Products Administration...
Celling Biotechnology’s CEL001 Earns Tacit Approval for Clinical Trials in China
Celling Biotechnology Co., Ltd, a Guangzhou-based biopharmaceutical company, has announced that its pipeline candidate CEL001...
Sino Biopharmaceutical’s Rovadicitinib Gets CDE Nod for Review in Myelofibrosis
Sino Biopharmaceutical Ltd (HKG: 1177) has announced that the Center for Drug Evaluation (CDE) in...
Sichuan Huiyu’s HY07121 Antifungal Protein Earns NMPA Review for Clinical Trials
Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553), a Chinese biopharmaceutical company, has announced that the...
Betta Pharmaceuticals’ EYP-1901 Implant Secures NMPA Clinical Trial Nod for Wet AMD
Betta Pharmaceuticals (SHE: 300558) has announced that it has received clinical trial approval from China’s...
Shenzhen Tyercan Bio-Pharma’s TYE1001 Earns Tacit IND Approval from FDA for Advanced Solid Tumors
Shenzhen Tyercan Bio-pharm Co., Ltd, a biopharmaceutical company based in China, has announced that it...
Mabwell Bioscience Receives NMPA Approval for Phase II TNBC Clinical Trial of 9MW2821
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that China’s National Medical Products Administration...
Lionco Pharmaceutical Partners with Laboratoire Bailly-Creat to Expand Overseas
Shanghai-based Lionco Pharmaceutical Group (SHA: 603669) has entered into a strategic partnership framework agreement with...
Novo Nordisk Faces US Senators’ Scrutiny Over Levemir Withdrawal
US senators, including Jeanne Shaheen, Raphael Warnock, and Elizabeth Warren, have voiced concerns over Novo...
Johnson & Johnson Appoints Edward Zhou as Medtech China President
Johnson & Johnson (J&J, NYSE: JNJ), a global healthcare giant, has announced the appointment of...
Ipsen S.A. Receives NMPA Green Light for Six-Month Diphereline Dosage in Central Precocious Puberty
Ipsen S.A. (EPA: IPN; OTCMKTS: IPSEY) has announced that it has received marketing approval from...
Shanghai HeartCare Medical Secures Taiwan Approval for Homegrown Femoral Artery Occluder
Shanghai HeartCare Medical Technology Co., Ltd (HKG: 6609), a leading player in the Chinese medical...